Short Interest Sector Focus: Industrials Sector

As of the close of business on Tuesday, 8/30, we captured the Top 10 Highest Short Interest % stocks within the Industrials Sector. The average short interest for stocks within the Industrials sector stands at 2.65%. Therefore, the below stocks are showing a more pessimistic outlook than their peers within the respective sector.  

As of the close of business on Tuesday, 8/30, we captured the Top 10 Highest Short Interest % stocks within the Industrials Sector.

The average short interest for stocks within the Industrials sector stands at 2.65%. Therefore, the below stocks are showing a more pessimistic outlook than their peers within the respective sector.

 

  • AGRIFY CORPORATION    (NASDAQ:AGFY)    35.24%
  • VIRGIN GALACTIC HL    (NYSE:SPCE)    30.90%
  • XOMETRY INC        (NASDAQ:XMTR)    22.17%
  • 3M COMPANY        (NYSE:MMM)    21.80%
  • CHART INDUSTRIES    (NYSE:GTLS)    18.54%
  • FLUOR CORP        (NYSE:FLR)    16.46%
  • FUELCELL ENERGY        (NASDAQ:FCEL)    15.01%
  • AMMO INC        (NASDAQ:POWW)    14.97%
  • LIGHTNING EMOTORS    (NYSE:ZEV)    14.23%
  • PLUG POWER INC        (NASDAQ:PLUG)    13.85%

Short Interest is the percentage of a stocks’ outstanding shares being sold short, which is utilized as a gauge for stock price sentiment. When short interest increases, this is generally considered a negative “bear” market indicator, whereas when short interest decreases, this is generally considered a positive “bull” market indicator. 

Disclaimer:
The Short Interest Indicator is produced by Tidal Markets, in partnership with Benzinga Insights. The data represented is exclusive to short interest data amalgamated daily by Tidal Markets LLC and its underlying proprietary sources. The information contained herein should not be compared to, contrasted, or evaluated against other short interest data providers. ANY INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE OR IMPLY INVESTMENT ADVICE

Total
0
Shares
Related Posts
Read More

IDEAYA Announces Interim Phase 2 Data for Darovasertib and Crizotinib Combination and Successful FDA Type C Meeting on Registrational Trial Design for Accelerated Approval in First-Line Metastatic Uveal Melanoma; Confirmed Overall Response Rate Of 45%,…

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) announced further interim results from its Phase 2 clinical trial evaluating darovasertib and crizotinib combination in metastatic uveal melanoma (MUM) patients (ClinicalTrials.gov Identifier: NCT03947385).

IDYA